Direct-acting antiviral (DAA) therapy is highly efficacious for the treatment of hepatitis C virus (HCV) infection in older adults; however, those aged ≥75 years are more likely to have clinically significant pretreatment drug-drug interactions (DDIs) and experience adverse events (AEs) during therapy. This according to a retrospective review between June 2014 and January 2017 that included individuals aged ≥65 years treated with DAA therapy for HCV during the study period (n=113) divided into 2 cohorts: aged 65 to 74 years (n=88) and aged ≥75 years (n=25). DDIs, AEs, and rates of sustained virologic response (SVR) with DAA therapy were assessed. Among the findings:
- SVR rate was 97.7% in those aged 65 to 74 years and 95.8% in those aged ≥75 years.
- Individuals aged ≥75 years were more likely to be taking >2 medications per day for chronic conditions and more likely to have clinically significant DDIs necessitating cessation or adjustment of medications before inauguration of DAA therapy.
- Those aged ≥75 years were also more likely to experience an AE during therapy.
Mazzarelli C, Considine A, Childs K, et al. Efficacy and tolerability of direct-acting antivirals for hepatitis C in older adults. [Published online ahead of print May 25, 2018]. J Am Geriatr Soc. doi:10.1111/jgs.15392.
This Week's Must Reads
Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al
Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al
Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al
Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al
Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al
Must Reads in Hepatitis
Glecaprevir/pibrentasvir Can Reduce HCV Tx Duration, Hepatol Int; ePub 2018 May 29; Abutaleb, et al
Estimates of HCV by Race and Sex in US, BMC Infect Dis; ePub 2018 May 16; Hall, et al
Efficacy of DAA Therapy for HCV in Older Adults, J Am Geriatr Soc; ePub 2018 May 25; Mazzarelli, et al
HCV Treatment in People Who Inject Drugs, Open Forum Infect Dis; ePub 2018 May 23; Alimohammadi, et al
Risk of HCV Among Vulnerable Populations, J Viral Hepat; ePub 2018 May 31; Aisyah, et al